L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 5.06 NOK 0.8%
Market Cap: 345.4m NOK
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one LYTIX stock under the Base Case scenario is hidden NOK. Compared to the current market price of 5.06 NOK, Lytix Biopharma AS is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LYTIX Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

32.1
P/S
P/S
Price to Sales
32.1
vs History
61
vs Industry
25
Median 3Y
47.9
Median 5Y
45.8
Industry
7.2
Forward
37.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-7.5
Median 5Y
-8.9
Industry
21.4
Forward
-1.8
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-7.1
Industry
20.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.9
Median 5Y
-7
Industry
24.5
More Details
9.4
P/B
P/B
Price to Book Value
9.4
vs History
25
vs Industry
9
Median 3Y
6.1
Median 5Y
5
Industry
2.4
More Details
26.8
EV/S
EV/S
Enterprise Value to Sales
26.8
vs History
61
vs Industry
22
Median 3Y
42
Median 5Y
36.4
Industry
7.4
Forward
32.4
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-6.2
Industry
4.1
Forward
-2.2
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-6.1
Industry
3.8
Forward
-2.2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-6
Industry
5.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-6
Industry
3.3
More Details
28
EV/IC
EV/IC
Enterprise Value to IC
28
vs History
65
vs Industry
8
Median 3Y
45.9
Median 5Y
45.9
Industry
4.4
More Details

Multiples Across Competitors

LYTIX Competitors Multiples
Lytix Biopharma AS Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Lytix Biopharma AS
OSE:LYTIX
329.7m NOK 32.1 -4.3 -3.6 -3.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 746 104.5 -174 648.8 -212 079.3 -209 659.2
US
Abbvie Inc
NYSE:ABBV
357.9B USD 6.4 84.4 16.6 25
US
Amgen Inc
NASDAQ:AMGN
164.2B USD 4.9 40.1 16.2 28.8
US
Gilead Sciences Inc
NASDAQ:GILD
138.5B USD 4.8 288.6 11.3 14.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.1B USD 11.7 -241.1 26.4 27.7
US
Epizyme Inc
F:EPE
94.1B EUR 1 917.2 -489.2 -532.7 -518.5
AU
CSL Ltd
ASX:CSL
121.8B AUD 5.1 28.1 17.2 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
69.7B USD 4.9 15.8 10.2 11.4
US
Seagen Inc
F:SGT
39.3B EUR 18.5 -56.6 -60.9 -55
NL
argenx SE
XBRU:ARGX
33.1B EUR 16.3 42.9 315.4 -2 323.6
P/S Multiple
Revenue Growth P/S to Growth
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average P/S: 3 340 738.8
32.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
36 746 104.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
E
Epizyme Inc
F:EPE
1 917.2
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.9
7%
0.7
US
S
Seagen Inc
F:SGT
18.5
30%
0.6
NL
argenx SE
XBRU:ARGX
16.3
37%
0.4
P/E Multiple
Earnings Growth PEG
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average P/E: 83.3
Negative Multiple: -4.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -174 648.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
84.4
88%
1
US
Amgen Inc
NASDAQ:AMGN
40.1
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
288.6
185%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.1 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -489.2 N/A N/A
AU
CSL Ltd
ASX:CSL
28.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.8
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.6 N/A N/A
NL
argenx SE
XBRU:ARGX
42.9
19%
2.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average EV/EBITDA: 59.1
Negative Multiple: -3.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -212 079.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.2
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
11.3
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.4
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.2
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.9 N/A N/A
NL
argenx SE
XBRU:ARGX
315.4
166%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average EV/EBIT: 21.4
Negative Multiple: -3.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 659.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
28.8
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.7
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -518.5 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.4
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 323.6 N/A N/A

See Also

Summary
LYTIX intrinsic value, competitors valuation, and company profile.
DCF Valuation
LYTIX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LYTIX stock valuation using valuation multiples.
Wall Street Estimates
LYTIX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LYTIX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 242,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.